Abstract
Oxitropium (Oxivent – Boehringer) has recently been introduced as a metered dose inhaler for regular use in chronic stable asthma and chronic obstructive bronchitis. Like ipratropium (Atrovent) which we have previously reviewed,1 it blocks the muscarinic cholinergic receptors which mediate smooth muscle contraction in the airways. The manufacturer claims that regular use of oxitropium (200μg twice or three times daily) reduces the incidence of symptoms, including the need for night-time bronchodilators, and improves lung function in some patients; it is not intended for immediate symptom relief. Promotion describes oxitropium as ‘breaking the mould’ and offering ‘a step forward for those not simply asthmatic’. Is it just another ipratropium?
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
